Diagnos(OTC) DGNOF

Market Cap$19.39M

Since IPO (2012)-88%

5 Year-67%

1 Year+1%

1 Month-6%

$0.15

-6.83%

-0.01Today

Diagnos last closing stock price
Metric	Price	Date
Last close	USD 0.15	2026-07-27

Diagnos stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-7.18%	USD 0.16	2026-07-20
1 month	-6.25%	USD 0.16	2026-06-26
3 month	-7.98%	USD 0.16	2026-04-28
Year to date	-43.33%	USD 0.26	2025-12-31
1 year	+1.32%	USD 0.15	2025-07-25
3 year	-55.96%	USD 0.34	2023-07-28
5 year	-66.73%	USD 0.45	2021-07-16
Since inception	-87.8%	USD 1.23	2012-07-30

Diagnos Financials at a Glance

Market Cap

$19.39M

Revenue (TTM)

CA$65.50K

Net Income (TTM)

-CA$4.56M

EPS (TTM)

-$0.03

P/E Ratio

-5.39

Dividend

$0.00

Beta (Volatility)

0.26 (Low)

Dividend

$0.00

Beta (Volatility)

0.26 (Low)

Price

$0.15

Volume

17,000

Open

$0.17

Price

$0.15

Volume

17,000

Open

$0.17

Previous Close

$0.15

Daily Range

$0.15 - $0.17

52-Week Range

$0.13 - $0.29

Estimated Earnings Date

Jun 4, 2026

Dividend

$0.00

Beta (Volatility)

0.26 (Low)

Price

$0.15

Volume

17,000

Open

$0.17

Previous Close

$0.15

Daily Range

$0.15 - $0.17

52-Week Range

$0.13 - $0.29

Estimated Earnings Date

Jun 4, 2026

DGNOF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Diagnos

DIAGNOS Inc. specializes in technology-driven services primarily in the healthcare sector. The company is known for its innovative Computer Assisted Retina Analysis (CARA) software, which aids in the detection of diabetic retinopathy.

Products and Services

Computer Assisted Retina Analysis (CARA) software for eye care professionals
Consulting services in data analytics and artificial intelligence
Healthcare technology solutions across multiple countries

Growth Outlook

Expansion into international markets, including the U.S. and Colombia
Increasing demand for diabetic retinopathy screening solutions
Focus on enhancing software capabilities and user experience

Financial Highlights

Recent quarterly revenue of CAD 15,750, showing consistent performance
Trailing twelve months (TTM) net income margin of -69.57%, indicating operational challenges
Current ratio of 1.49, suggesting adequate short-term financial health

DIAGNOS Inc. has established itself as a key player in the healthcare technology sector, particularly with its CARA software, which is crucial for diagnosing diabetic retinopathy. The company operates in various countries, enhancing its market reach and potential for growth. Despite facing operational challenges reflected in its financial metrics, the current ratio indicates a solid short-term financial position. The focus on expanding its software capabilities and entering new markets positions DIAGNOS for future growth, making it an intriguing option for investors interested in healthcare technology.

AI Generated • Jul 3, 2026

Industry

Health Care Technology

Sector

Health Care

CEO

André M. Larente

Website

www.diagnos.com

Headquarters

Brossard, QC J4Z 1A7, CA

DGNOF Financials

Key Financial Metrics (TTM)

Gross Margin

-182.42%

Operating Margin

-6510.52%

Net Income Margin

-6956.84%

Return on Equity

11659.44%

Return on Capital

-204.11%

Return on Assets

-190.55%

Earnings Yield

-18.55%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$19.39M

Shares Outstanding

120.41M

Volume

17.00K

Avg. Volume

95.13K

Financials (TTM)

Gross Profit

-CA$1.49M

Operating Income

-CA$4.23M

EBITDA

-CA$4.06M

Operating Cash Flow

-CA$3.86M

Capital Expenditure

-CA$11.07K

Free Cash Flow

-CA$3.87M

Cash & ST Invst.

CA$1.93M

Total Debt

CA$1.41M

Diagnos Performance Analysis

Diagnos annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2023	2023-03-31	CAD 367,189	4.9%
2024	2024-03-31	CAD 126,152	-65.6%
2025	2025-03-31	CAD 74,624	-40.8%
2026	2026-03-31	CAD 47,376	-36.5%

Diagnos sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q1	2025-06-30	5.5%
Q2	2025-09-30	-21.9%
Q3	2025-12-31	0.2%
Q4	2026-03-31	3.7%

Diagnos annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2023	2023-03-31	CAD -0.03	-11.2%
2024	2024-03-31	CAD -0.03	18.2%
2025	2025-03-31	CAD -0.03	9.7%
2026	2026-03-31	CAD -0.03	-12.6%

Diagnos sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q1	2025-06-30	19.3%
Q2	2025-09-30	1.8%
Q3	2025-12-31	7.5%
Q4	2026-03-31	1.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q4 2026YOY CHG

Revenue

CA$15.75K

-14.4%

Gross Profit

-CA$352.82K

-21.5%

Gross Margin

-22.40%

N/A

Market Cap

$19.39M

N/A

Market Cap/Employee

$881.42K

N/A

Employees

N/A

Net Income

-CA$1.19M

+11.2%

EBITDA

-CA$1.12M

+3.2%

Quarterly Fundamentals

Name

Q4 2026YOY CHG

Total Cash

CA$1.93M

-40.3%

Total Debt

CA$1.41M

-54.3%

Accounts Receivable

CA$212.93K

+39.7%

Inventory

CA$0.00

N/A

Long Term Debt

CA$226.29K

-20.9%

Short Term Debt

CA$1.18M

-57.8%

Return on Assets

-1.91%

N/A

Return on Invested Capital

-4.67%

N/A

Free Cash Flow

-CA$1.32M

-6.0%

Operating Cash Flow

-CA$1.32M

-6.0%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

POSCPositron Corporation

POSCPositron Corporation$1.57-6.55%

CRVWCareView Communications, Inc.

CRVWCareView Communications, Inc.$0.04+0.00%

CLYYFCelyad Oncology S.A.

CLYYFCelyad Oncology S.A.$0.20+0.00%

IPDQFImpediMed Limited

IPDQFImpediMed Limited$0.00-40.00%

AHGIFAlternate Health Corp.

AHGIFAlternate Health Corp.$0.00+0.00%

MRAIMarpai, Inc.

MRAIMarpai, Inc.$2.24-5.49%

BBIXFBonus Biogroup Ltd.

BBIXFBonus Biogroup Ltd.$0.10+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF$5.25+0.10%

NOKNokia

NOKNokia$9.28+0.02%

AALAmerican Airlines Group

AALAmerican Airlines Group$14.95+0.03%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$7.24-0.02%

TAT&T

TAT&T$24.42+0.01%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$63.40-0.01%

SOFISoFi Technologies

SOFISoFi Technologies$16.88+0.03%

Questions About DGNOF

What is the current price of Diagnos?

Diagnos is trading at $0.15 per share.

What is the 52-week range for Diagnos?

Over the past 52 weeks, Diagnos has traded between $0.13 and $0.29.

How much debt does Diagnos have?

As of the most recent reporting period, Diagnos reported total debt of CA$1.00M.

How much cash does Diagnos have on hand?

Diagnos reported CA$222.14K in cash and cash equivalents in its most recent financial results.

What is Diagnos’s dividend yield?

Diagnos does not currently have a dividend yield.

Diagnos(OTC) DGNOF

Diagnos Financials at a Glance

DGNOF News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Diagnos

DGNOF Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Diagnos Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About DGNOF

What is the current price of Diagnos?

What is the 52-week range for Diagnos?

How much debt does Diagnos have?

How much cash does Diagnos have on hand?

What is Diagnos’s dividend yield?

Premium Investing Services